EVP Chief Patient & Ext Af Off

EVP, Chief Reg. & Quality Off.

Director

EVP, Chief Commercial Officer

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Institution	Shares	Value	Change
Assenagon Asset Management	759,564	$377M	INCREASED
Robeco Institutional Asset Management B.V	404,396	$201M	INCREASED
Swedbank AB	282,444	$140M	INCREASED
Handelsbanken Fonder AB	218,292	$108M	DECREASED
Mirae Asset Global Investments Co., Ltd	210,209	$104M	INCREASED

Insider	Type	Shares	Value	Date
Amit Sachdev (EVP Chief Patient & Ext Af Off)	AWARD	8,251		2026-07-21
Ourania Tatsis (EVP, Chief Reg. & Quality Off.)	AWARD	8,251		2026-07-21
Alan M Garber (Director)	AWARD	31	$15K	2026-07-15
Bruce I Sachs (Director)	AWARD	99	$47K	2026-07-15
Duncan Mckechnie (EVP, Chief Commercial Officer)	SELL	1,541	$800K	2026-07-02

Member	Type	Amount	Date
Alan Armstrong (Republican)	PURCHASE	$1,001 - $15,000	2026-03-27
Ro Khanna (Democrat)	PURCHASE	$1,001 - $15,000	2026-04-13

Vertex Pharmaceuticals Inc (VRTX) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades